Albuterol-sulphate

Phase 3Small molecule

NNYU Langone Health

Albuterol-sulphate is one of 6 small molecule programs targeting Familial dysautonomia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial DysautonomiaActive, not recruiting

Familial DysautonomiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Familial Dysautonomia

#DrugCompanyPhaseTrials

Proair HFA

GGlaxo Dba Glaxosmithkline

Lodosyn

1 3

Atrovent

Boehringer Ingelheim

Phase 3

1 4

Marinol

Alnylam Pharmaceuticals

Phase 2

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 6

Albuterol-sulphate

NNYU Langone Health

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial dysautonomia1 trial

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

Completed·NNYU Langone Health·Phase 3·NCT01987219·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Albuterol-sulphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albuterol-sulphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albuterol-sulphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNYU Langone Health

Albuterol-sulphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial dysautonomia1 trial

References

Drug Info

Quick Facts

Related News